<DOC>
	<DOCNO>NCT00171613</DOCNO>
	<brief_summary>The extension protocol design allow patient randomize placebo core portion protocol receive 6 month treatment open label octreotide allow patient randomize octreotide appeared benefit treatment , continue receive octreotide .</brief_summary>
	<brief_title>A Study Octreotide Depot v Saline Control Pediatric Hypothalamic Obesity Patients</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Inclusion Criteria Patient must provide write informed consent Exclusion Criteria Any patient experience unresolved safety complication time original protocol CSMS995B2403 Patients history gallstone patient develop gallstone course core protocol Patients safety tolerability concern continue Octreotide Depot Any patient require additional treatment original cranial insult relate cranial trauma , tumor recurrence treatment Refer original protocol detail inclusion &amp; exclusion criterion . Any patient grant waiver participate core protocol allow continue participate extension protocol . Other protocoldefined inclusion / exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Obesity</keyword>
</DOC>